Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dabie bandavirus antigens encoded by GLS-5140 refer to the structural proteins of the virus—specifically the envelope glycoproteins (Gn and Gc) and the nucleoprotein (NP)—that are expressed in vivo following the administration of the GLS-5140 DNA vaccine (Source: GeneOne LifeScience). Dabie bandavirus, formerly known as Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV), is a tick-borne phenuivirus that causes a severe hemorrhagic fever with high mortality rates (Source: WHO). The Gn and Gc glycoproteins are critical for viral entry, mediating attachment to host receptors and pH-dependent membrane fusion, while the NP protein is essential for viral RNA encapsidation and replication (Source: PubMed PMID: 31235547). By delivering the genetic sequences for these antigens, GLS-5140 prompts the host's immune system to recognize these viral components as foreign. This process induces a dual immune response involving the production of neutralizing antibodies that prevent viral infection and the activation of T-cells that clear infected cells (Source: ClinicalTrials.gov NCT04284826). This target is central to the development of prophylactic interventions against SFTS, for which no specific antiviral treatments or vaccines are currently widely available. Clinical evaluation of these antigens as vaccine targets is ongoing to determine their safety and efficacy in human populations.
GLS-5140 is a DNA vaccine that, upon delivery into host cells via electroporation, utilizes the host's cellular machinery to express Dabie bandavirus antigens (Gn, Gc, and NP). These expressed proteins are then presented to the immune system to trigger the production of neutralizing antibodies and activate T-cell mediated immune responses, providing prophylactic protection against the virus (Source: GeneOne LifeScience; PubMed PMID: 31235547).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dabie bandavirus envelope glycoproteins (Gn and Gc) and nucleoprotein (NP) (SFTSV Gn/Gc/NP).